Korean Tickers
KRX in English
HomeMarketsStocksFinancialsGuide
NewsfeedInsightsEarningsBroker research
AI Value ChainAPI overviewPricingDocumentationPlan & billing
X
Korean Tickers
KRX in English
HomeMarketsStocksFinancialsGuide
NewsfeedInsightsEarningsBroker research
AI Value ChainAPI overviewPricingDocumentationPlan & billing
XSign in

Market Pulse

Daily · Sep 22, 2026 · data.go.kr + ECOS
KOSPI
7,017.91
+10.19 (+0.15%)
KOSDAQ
834.38
-1.89 (-0.23%)
KOSPI 200
1,113.30
+1.14 (+0.10%)
USD/KRW
1,366.00
Home›Reports›069620
069620KOSPI·May 14, 2026

Efforts to streamline prescription drug channels underway

DAEWOONG PHARMAMirae Asset SecuritiesSeung-min Kim

Mirae Asset Securities published a company analysis report on DAEWOONG PHARMA (069620) titled "Efforts to streamline prescription drug channels underway".

Summary
Covers DAEWOONG PHARMA (069620).
Covered stock
069620
DAEWOONG PHARMA
KOSPI · Company Analysis
Stock page →
More on 069620
Early Nabota shipments lift earningsMirae Asset Securities · Jul 31, 2026Initiating Coverage: New Business Potential; Discount to NarrowKB Securities · May 27, 2026Compelling valuationMirae Asset Securities · Nov 10, 2025Strong margin growthMirae Asset Securities · Feb 11, 2025
KOSPI
Efforts to streamline prescription drug channels underway
Mirae Asset Securities
DAEWOONG PHARMA logo
Source
Mirae Asset Securities
PDF
Open report PDF →
Report facts
BrokerMirae Asset Securities
AnalystSeung-min Kim
Publication dateMay 14, 2026
RatingBuy
Target price-
CollectedJun 03, 2026
Use the publisher link for the complete report. Korean Tickers shows report metadata and a short overview.
Korean Tickers·Research reference for Korean listed companies.
API overviewPricingDocumentationPlan & billing
Prices use KIS quote snapshots with data.go.kr daily fallback. Financials use DART; macro data uses ECOS.·Market data is informational and not investment advice.
KIS snapshots are refreshed every 30 minutes and are not a streaming quote feed.·Sources
TermsRefundsDisclaimerPrivacy